May 22, 2020 / 11:22 PM / 13 days ago

BRIEF-Dupixent Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints

May 22 (Reuters) - Sanofi SA:

* DUPIXENT® (DUPILUMAB) EOSINOPHILIC ESOPHAGITIS TRIAL MEETS BOTH CO-PRIMARY ENDPOINTS

* SANOFI - PHASE 3 TRIAL MET BOTH OF ITS CO-PRIMARY ENDPOINTS, AS WELL AS ALL KEY SECONDARY ENDPOINTS

* SANOFI - PHASE 3 TRIAL DEMONSTRATED SIMILAR SAFETY RESULTS TO KNOWN SAFETY PROFILE OF DUPIXENT IN ITS APPROVED INDICATIONS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below